AUTL

Autolus Therapeutics plc

3.73 USD
-0.10 (-2.61%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Autolus Therapeutics plc stock is down -4.85% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 6 June’s closed higher than May. In the last 1 Unusual Options Trades, there were 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
07 Jun 18:37 21 Jun, 2024 5.00 PUT 364 397

About Autolus Therapeutics plc

Autolus Therapeutics plc develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trials for adult ALL. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development.

  • Needham
    Mon Jun 17, 05:49
    buy
    confirm
  • Needham
    Mon Jun 3, 06:06
    buy
    confirm